HRP20020205B1 - Disperzijske formulacije koje sadrže inhibitore lipaze - Google Patents

Disperzijske formulacije koje sadrže inhibitore lipaze

Info

Publication number
HRP20020205B1
HRP20020205B1 HR20020205A HRP20020205A HRP20020205B1 HR P20020205 B1 HRP20020205 B1 HR P20020205B1 HR 20020205 A HR20020205 A HR 20020205A HR P20020205 A HRP20020205 A HR P20020205A HR P20020205 B1 HRP20020205 B1 HR P20020205B1
Authority
HR
Croatia
Prior art keywords
formulations containing
lipase inhibitors
dispersion formulations
containing lipase
polyoxyethylene
Prior art date
Application number
HR20020205A
Other languages
English (en)
Croatian (hr)
Inventor
Christiaan De Smidt Passchier
Hadvary Paul
Lengsfeld Hans
Rades Thomas
Steffen Hans
Tardio Joseph
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020205(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20020205A2 publication Critical patent/HRP20020205A2/xx
Publication of HRP20020205B1 publication Critical patent/HRP20020205B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20020205A 1999-09-13 2000-09-11 Disperzijske formulacije koje sadrže inhibitore lipaze HRP20020205B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99118180 1999-09-13
PCT/EP2000/008858 WO2001019340A1 (en) 1999-09-13 2000-09-11 Dispersion formulations containing lipase inhibitors

Publications (2)

Publication Number Publication Date
HRP20020205A2 HRP20020205A2 (en) 2004-04-30
HRP20020205B1 true HRP20020205B1 (hr) 2011-06-30

Family

ID=8238990

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020205A HRP20020205B1 (hr) 1999-09-13 2000-09-11 Disperzijske formulacije koje sadrže inhibitore lipaze

Country Status (38)

Country Link
US (3) US20030181512A1 (cs)
EP (1) EP1216025B1 (cs)
JP (1) JP4217016B2 (cs)
KR (1) KR100572434B1 (cs)
CN (1) CN1197551C (cs)
AR (1) AR025587A1 (cs)
AT (1) ATE333866T1 (cs)
AU (1) AU769415B2 (cs)
BR (2) BRPI0013939B1 (cs)
CA (1) CA2383916C (cs)
CO (1) CO5180587A1 (cs)
CY (1) CY1106180T1 (cs)
CZ (1) CZ301901B6 (cs)
DE (1) DE60029602T2 (cs)
DK (1) DK1216025T3 (cs)
EG (1) EG24117A (cs)
ES (1) ES2267563T3 (cs)
HR (1) HRP20020205B1 (cs)
HU (1) HU228858B1 (cs)
IL (1) IL148494A0 (cs)
JO (1) JO2386B1 (cs)
MA (1) MA26818A1 (cs)
ME (1) ME00674B (cs)
MX (1) MXPA02002034A (cs)
MY (1) MY130200A (cs)
NO (1) NO331906B1 (cs)
NZ (1) NZ517545A (cs)
PE (1) PE20010595A1 (cs)
PL (1) PL199870B1 (cs)
PT (1) PT1216025E (cs)
RS (1) RS50422B (cs)
RU (1) RU2239428C2 (cs)
SI (1) SI1216025T1 (cs)
TR (1) TR200200606T2 (cs)
TW (1) TWI243060B (cs)
UY (1) UY26338A1 (cs)
WO (1) WO2001019340A1 (cs)
ZA (1) ZA200201518B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8969901A (en) 2000-07-28 2002-02-13 Hoffmann La Roche New pharmaceutical composition
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
US8241664B2 (en) * 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
DE602007008567D1 (de) * 2007-09-12 2010-09-30 Mader S R L Pharmazeutische Zusammensetzungen zur oralen Verabreichung bei der Behandlung von Adipositas-Patienten
EP2044930A1 (en) * 2007-10-01 2009-04-08 Nestec S.A. Composition for controlling lipase catalyzed reactions
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
KR20100075260A (ko) * 2008-12-24 2010-07-02 주식회사종근당 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
BR112017021995A2 (pt) * 2015-04-14 2018-07-10 Zim Laboratories Ltd formulação farmacêutica compreendendo drogas de baixa fusão e altamente lipofílicas e método de melhora da dissolução
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法
MY196635A (en) * 2018-06-22 2023-04-25 Sime Darby Plantation Intellectual Property Sdn Bhd Method For Reducing Formation of Free Fatty Acids in Plants
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
CN114983938A (zh) * 2022-05-19 2022-09-02 广东嘉博制药有限公司 一种奥利司他口服复合乳液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034607A1 (en) * 1997-02-05 1998-08-13 F. Hoffmann-La Roche Ag Tetrahydrolipstatin containing compositions
WO1998034630A1 (en) * 1997-02-05 1998-08-13 F.Hoffmann-La Roche Ag Use of gastrointestinal lipase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
SU1510148A1 (ru) * 1988-01-26 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения ингибитора липазы
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
IT1282673B1 (it) 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
EP1017366A4 (en) 1996-09-01 2006-03-22 Pharmos Corp SOLID COPARCIPITATES FOR IMPROVED BIOVERABILITY OF LIPOPHILIC SUBSTANCES
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
KR20010079636A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034607A1 (en) * 1997-02-05 1998-08-13 F. Hoffmann-La Roche Ag Tetrahydrolipstatin containing compositions
WO1998034630A1 (en) * 1997-02-05 1998-08-13 F.Hoffmann-La Roche Ag Use of gastrointestinal lipase inhibitors

Also Published As

Publication number Publication date
BRPI0013939B1 (pt) 2017-07-18
DE60029602D1 (de) 2006-09-07
PT1216025E (pt) 2006-12-29
AU769415B2 (en) 2004-01-29
TWI243060B (en) 2005-11-11
MA26818A1 (fr) 2004-12-20
NO331906B1 (no) 2012-04-30
CZ20021276A3 (cs) 2003-04-16
SI1216025T1 (sl) 2006-12-31
HRP20020205A2 (en) 2004-04-30
MXPA02002034A (es) 2002-08-20
RU2239428C2 (ru) 2004-11-10
RS50422B (sr) 2009-12-31
JO2386B1 (en) 2007-06-17
AR025587A1 (es) 2002-12-04
CN1373656A (zh) 2002-10-09
KR20020063852A (ko) 2002-08-05
ATE333866T1 (de) 2006-08-15
HU228858B1 (en) 2013-06-28
US20040175420A1 (en) 2004-09-09
BR0013939A (pt) 2002-05-14
PL199870B1 (pl) 2008-11-28
US20030181512A1 (en) 2003-09-25
PL356174A1 (en) 2004-06-14
CA2383916C (en) 2009-01-20
DE60029602T2 (de) 2007-07-26
TR200200606T2 (tr) 2002-07-22
DK1216025T3 (da) 2006-10-30
PE20010595A1 (es) 2001-05-26
YU17202A (sh) 2006-01-16
CZ301901B6 (cs) 2010-07-28
NO20021204L (no) 2002-03-12
JP2003509357A (ja) 2003-03-11
MEP90808A (en) 2011-12-20
JP4217016B2 (ja) 2009-01-28
CY1106180T1 (el) 2011-06-08
US8012494B2 (en) 2011-09-06
IL148494A0 (en) 2002-09-12
KR100572434B1 (ko) 2006-04-18
ZA200201518B (en) 2003-07-30
HUP0202737A2 (hu) 2003-01-28
EP1216025B1 (en) 2006-07-26
WO2001019340A1 (en) 2001-03-22
ME00674B (me) 2011-12-20
AU7286300A (en) 2001-04-17
NO20021204D0 (no) 2002-03-12
US20110275706A1 (en) 2011-11-10
NZ517545A (en) 2003-11-28
ES2267563T3 (es) 2007-03-16
EG24117A (en) 2008-07-06
CN1197551C (zh) 2005-04-20
MY130200A (en) 2007-06-29
HUP0202737A3 (en) 2005-01-28
CA2383916A1 (en) 2001-03-22
UY26338A1 (es) 2000-10-31
EP1216025A1 (en) 2002-06-26
HK1049966A1 (en) 2003-06-06
CO5180587A1 (es) 2002-07-30

Similar Documents

Publication Publication Date Title
HRP20020205B1 (hr) Disperzijske formulacije koje sadrže inhibitore lipaze
ATE215359T2 (de) Aerosolformulierungen
ES2169121T3 (es) Composiciones farmaceuticas que contienen agentes inhibidores de proteasa de hiv.
PT762896E (pt) Composicoes de tocoferol para administracao de agentes biologicamente activos
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
ATE257695T1 (de) Fluorkohlenwasserstoff-treibgas enthaltende medizinische aerosole
AU2002316811A1 (en) Stable formulation of modified glp-1
NO991152D0 (no) Stabil farmas°ytisk blanding inneholdende 4,5-epoksy-morfinan-derivat
EP1145719A3 (en) Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
MY127749A (en) Liquid formulation
DK1073467T3 (da) Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D
PT896534E (pt) Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino
ES2108422T3 (es) Combinaciones sinergicas de productos antisolares y composiciones cosmeticas y dermatologicas que las contienen.
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
DE60116359D1 (de) Kahalalid f formulierung
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
AU3777197A (en) Cyclosporin formulation
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
ES2191426T3 (es) Composiciones estables que comprenden levosimendano y acido alginico.
MX9602984A (es) Composiciones farmaceuticas que contienen inhibidores de proteasa de vih.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: CHEPLAPHARM ARZNEIMITTEL GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190905

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200911